Cargando…

Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5–90 years

The recent development of assays that accurately quantify neurofilament light, a neuronal cytoskeleton protein, in plasma has generated a vast literature supporting that it is a sensitive, dynamic, and robust biomarker of neuroaxonal damage. As a result, efforts are now made to introduce plasma neur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simrén, Joel, Andreasson, Ulf, Gobom, Johan, Suarez Calvet, Marc, Borroni, Barbara, Gillberg, Christopher, Nyberg, Lars, Ghidoni, Roberta, Fernell, Elisabeth, Johnson, Mats, Depypere, Herman, Hansson, Caroline, Jonsdottir, Ingibjörg H, Zetterberg, Henrik, Blennow, Kaj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9297091/ https://www.ncbi.nlm.nih.gov/pubmed/35865350 http://dx.doi.org/10.1093/braincomms/fcac174

Ejemplares similares

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Harmonization and standardization of biofluid‐based biomarker measurements for AT(N) classification in Alzheimer's disease
por: Giangrande, Chiara, et al.
Publicado: (2023)

Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
por: Lewczuk, Piotr, et al.
Publicado: (2018)

Analytical and clinical validation of a blood progranulin ELISA in frontotemporal dementias
por: Meda, Francisco, et al.
Publicado: (2023)

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
por: Mattsson, Niklas, et al.
Publicado: (2016)

Serum neurofilament light protein predicts clinical outcome in traumatic brain injury
por: Shahim, Pashtun, et al.
Publicado: (2016)

Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis
por: Mens, Helene, et al.
Publicado: (2022)

Update on ultrasensitive technologies to facilitate research on blood biomarkers for central nervous system disorders
por: Andreasson, Ulf, et al.
Publicado: (2016)

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
por: Gisslén, Magnus, et al.
Publicado: (2015)

Thirty years after anorexia nervosa onset, serum neurofilament light chain protein concentration indicates neuronal injury
por: Wentz, Elisabet, et al.
Publicado: (2020)

Neurofilament light and tau as blood biomarkers for sports-related concussion
por: Shahim, Pashtun, et al.
Publicado: (2018)

Elevated plasma neurofilament light in aging reflects brain white‐matter alterations but does not predict cognitive decline or Alzheimer's disease
por: Nyberg, Lars, et al.
Publicado: (2020)

Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population
por: Gleerup, Helena Sophia, et al.
Publicado: (2021)

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid
por: Meda, Francisco J., et al.
Publicado: (2023)

Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer’s disease
por: Andersson, Emelie, et al.
Publicado: (2020)

Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140]
por: Gisslén, Magnus, et al.
Publicado: (2016)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease
por: Moscoso, Alexis, et al.
Publicado: (2021)

Increased CSF Levels of Phosphorylated Neurofilament Heavy Protein following Bout in Amateur Boxers
por: Neselius, Sanna, et al.
Publicado: (2013)

No change in plasma tau and serum neurofilament light concentrations in adolescent athletes following sport-related concussion
por: Wallace, Colin, et al.
Publicado: (2018)

BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease
por: Sjölander, Annica, et al.
Publicado: (2010)

Utility of plasma neurofilament light and total tau for clinical trials in Alzheimer's disease
por: Raket, Lars Lau, et al.
Publicado: (2020)

Serum and cerebrospinal fluid neurofilament light chain in patients with central nervous system infections caused by varicella-zoster virus
por: Tyrberg, Tobias, et al.
Publicado: (2020)

Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers
por: Camporesi, Elena, et al.
Publicado: (2021)

Lumbar and ventricular CSF concentrations of extracellular matrix proteins before and after shunt surgery in idiopathic normal pressure hydrocephalus
por: Minta, Karolina, et al.
Publicado: (2021)

Plasma neurofilament light chain concentration in the inherited peripheral neuropathies
por: Sandelius, Åsa, et al.
Publicado: (2018)

Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Exploring CSF neurofilament light as a biomarker for MS in clinical practice; a retrospective registry-based study
por: Rosenstein, Igal, et al.
Publicado: (2021)

Neurofilament light chain in the vitreous humor of the eye
por: Subramanian, Manju L., et al.
Publicado: (2020)

Neurogranin and Neurofilament Light Chain as Preclinical Biomarkers in Scrapie
por: Betancor, Marina, et al.
Publicado: (2022)

Evaluating Amyloid-β Oligomers in Cerebrospinal Fluid as a Biomarker for Alzheimer’s Disease
por: Hölttä, Mikko, et al.
Publicado: (2013)

Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
por: Cullen, Nicholas C., et al.
Publicado: (2020)

Corrigendum to “Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer’s disease” [Clin. Mass Spectrom. 14 (Part B) (2019) 74–82]
por: Hansson, Karl, et al.
Publicado: (2022)

Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS
por: Hölttä, Mikko, et al.
Publicado: (2012)

CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers
por: Rostgaard, Nina, et al.
Publicado: (2018)

Increased intrathecal neurofilament light and immunoglobulin M predict severe disability in relapsing-remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2022)

Neurofilament light chain and total tau in the differential diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies
por: Kmezic, Ivan, et al.
Publicado: (2022)

Screening for neurodegeneration in Langerhans cell histiocytosis with neurofilament light in plasma
por: Sveijer, Malin, et al.
Publicado: (2022)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
por: Bergman, Joakim, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_a8micb97p6nblpi2vh0cr0lhf8